This study focuses on children and adolescents who suffer from migraine, a condition that causes severe headaches often accompanied by sensitivity to light and sound, nausea, and other symptoms. The study will evaluate a medication called eptinezumab (also known as VYEPTI), which is given through intravenous administration (delivered directly into a vein).

The main purpose is to examine the long-term safety of eptinezumab in young patients aged 6 to 17 years who have either chronic migraine (frequent headaches occurring 15 or more days per month) or episodic migraine (less frequent headaches). The study will continue for 36 months, during which participants will receive the medication every 12 weeks.

During the study, doctors will monitor how the participants respond to the treatment by checking for any side effects and measuring the amount of medication in their blood. They will also assess how the treatment affects the participants’ daily activities and their ability to function at school and in other settings using special questionnaires designed for young people with migraine.